-
Gracell to Present the First-in-human, Universal TruUCAR™ GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Annual Meeting
SUZHOU, China and SHANGHAI, April 13, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell and gene therapy company, is pleased to announce that their first-in-human phase I data of Universal TruUCAR™ GC027 in relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)Apr 13, 2020
-
Gracell Announces China NMPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
SHANGHAI and SUZHOU, China, April 3, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell & gene therapy company, is pleased to announce that China National Medical Products Administration (NMPA) has accepted Gracell"s Investigational New Drug (IND) application for GC007g, aApr 03, 2020
-
Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR™ Therapy for Relapsed or Refractory T-cell Malignancies
SUZHOU, China and SHANGHAI, Jan. 7, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell therapy company, today announced the initiation of an investigational study of GC027, the first product candidate developed using TruUCAR™ to treat relapsed or refractory (R/R) T-cell malignancies. T-cell acuteJan 07, 2020
-
Gracell to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco
SHANGHAI and SUZHOU, China, Dec. 30, 2019 /PRNewswire/ -- Gracell Biotechnologies Co. Ltd., a clinical-stage immune cell therapy company, has announced it will present at leading healthcare conferences in San Francisco, California at the beginning of January 2020. Gracell will present at the 38th Annual J.P. Morgan Healthcare Conference,Dec 30, 2019
-
Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies
- FasTCAR-19 (GC007F) shows a high response rate, with 34 of 35 evaluable r/r B-ALL patients achieving CR on Day 28, where 32 patients achieving MRD negative CR - Dual CAR-19-22 (GC022) shows sound safety profile and effectiveness, with 15/16 evaluableDec 09, 2019
-
Gracell Announces Five Presentations at the Annual Meeting of American Society of Hematology (ASH)
SHANGHAI and SUZHOU, China, Nov. 15, 2019 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell therapy company, today announced five presentations to be delivered at the upcoming American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, held from December 7-10. The presentations centre onNov 15, 2019
-
Gracell Announces Interim Readout of Investigation for First-in-class FasT CAR-19 in patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and Extension in Use of FasT CAR to Other Immune Cell Programs
- The study shows a high response rate, with 23 of 24 treated patients achieving complete remission and 21 of 24 treated patients achieving undetectable minimal residual disease on 28 days of follow-up - All 26 patient samples were manufactured overnightSep 11, 2019
-
Gracell Data on Multi-center Investigation of FasT CAR-19 Therapy Shows Positive First Impact in Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Preliminary data shows a high response rate, with 16 of 16 patients achieving complete remission and 14 of 16 patients achieving undetectable minimal residual disease with mild side effect observed FasT CAR-19 (GC007F) can be manufactured overnight with 100% success FasT CAR-19Jun 20, 2019
-
Gracell Bio Announces FasT CAR-T, a Breakthrough Technology for Hematological Malignancies
Gracell conquers effective, low cost, and high speed manufacturing of cellular gene therapeutics SHANGHAI and SUZHOU, China, April 23, 2019 /PRNewswire/ -- Gracell Biotechnologies, Co., Ltd. ("Gracell"), an immune cell gene therapy company, announced it has developed FasT CAR-T, a revolutionary platformApr 23, 2019
-
Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies
Gracell addresses the issues of complex manufacture and high cost of cellular gene therapeutics SUZHOU and SHANGHAI, China, Feb. 25, 2019 /PRNewswire/ -- Gracell Biotechnologies, Co., Ltd. ("Gracell") announced the completion of its $85 million series B funding today. The financing wasFeb 25, 2019